

AL

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/00, 15/06, 15/09</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/58451</b> <b>(43) International Publication Date:</b> 5 October 2000 (05.10.00)
<b>(21) International Application Number:</b> PCT/US00/07544 <b>(22) International Filing Date:</b> 21 March 2000 (21.03.00)  <b>(30) Priority Data:</b> 09/277,078      26 March 1999 (26.03.99)      US  <b>(71) Applicant:</b> THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).  <b>(72) Inventors:</b> SAKURADA, Kazuhiro; 5220 Fiore Terrace #213, San Diego, CA 92122 (US). PALMER, Theo; 3491 Tony Drive, San Diego, CA 92122 (US). GAGE, Fred, H.; 1533 Virginia Way, La Jolla, CA 92037 (US).  <b>(74) Agent:</b> FULLER, Michael, L.; Knobbe, Martens, Olson & Bear, LLP, Sixteenth Floor, 620 Newport Center Drive, Newport Beach, CA 926609 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> REGULATION OF TYROSINE HYDROXYLASE EXPRESSION  <b>(57) Abstract</b> <p>The invention relates to methods and materials involved in the regulation of tyrosine hydroxylase expression as well as the treatment of catecholamine-related diseases. Specifically, the invention provides cells that contain exogenous nucleic acid having a nucleic acid sequence that encodes Nurrl as well as methods and materials for inducing tyrosine hydroxylase expression, treating catecholamine-related deficiencies, and identifying tyrosine hydroxylase-related deficiencies.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## REGULATION OF TYROSINE HYDROXYLASE EXPRESSION

### BACKGROUND

#### *1. Technical Field*

5           The invention relates generally to neural progenitor cells and more specifically to the regulation of tyrosine hydroxylase expression and treatment of catecholamine-related diseases.

#### *2. Background Information*

10           During development, neural stem cells differentiate into the different types of neurons and glia found in the adult central nervous system (CNS) and peripheral nervous system (PNS). In general, these different types of neurons are classified based on the particular types of neurotransmitters they produce. For example, dopaminergic neurons produce dopamine, while noradrenergic neurons produce  
15   norepinephrine. The neurotransmitters dopamine and norepinephrine belong to a class of compounds called catecholamines. A catecholamine is an ortho-dihydroxyphenylalkylamine that is derived from the common cellular metabolite tyrosine. For example, the catecholamines dopamine and norepinephrine are synthesized from tyrosine as follows: tyrosine is converted to  
20   dihydroxyphenylamine (DOPA) by the enzyme tyrosine hydroxylase (TH), DOPA to dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC), and dopamine to norepinephrine by the enzyme dopamine  $\beta$ -hydroxylase (DBH). The rate limiting step for both dopamine and norepinephrine synthesis is the conversion of tyrosine into DOPA by TH. In addition, dopamine can be converted to  
25   dihydroxyphenylacetic acid (DOPAC) by the enzymes monoamine oxidase (MAO) and aldehyde dehydrogenase.

          The exact mechanisms that regulate neuronal phenotype or even neuronal cell fate determination are not well understood. Developmental studies, however, have identified some genes that appear involved. Briefly, vertebrate nervous systems  
30   develop in stereotypic positions along the dorso-ventral (D-V) and anterior-posterior

(A-P) axes of the neural tube (Tanabe *et al.*, *Science* 274:1115-1123 (1996).

Transplantation and explant culture studies confirmed that signaling centers instruct cell fates along the A-P and D-V axes. A characteristic common to these centers is the interaction of receptor-ligand pairs to modify cell fate. Sonic hedgehog (Shh) and  
5 bone morphogenetic protein (BMP) are two such polypeptides that regulate cell fate along the D-V axis. Fibroblast growth factor-2 (FGF-2), FGF-8, retinoic acid (RA), and Wnt1 influence cell fate along the A-P axis. In each case, signaling induces downstream changes that are reflected in the patterning of transcription factor expression (Crossley *et al.*, *Nature* 380:66-68 (1996); Lumsden and Krumlauf,  
10 *Science* 274:1109-1114 (1996); Shimamura *et al.*, *Development* 124:2709-2718 (1997); and Vollmer *et al.*, *J. Neurochem.* 71:1-19 (1998)).

Using explant cultures, intersections of Shh and FGF-8 signaling created induction sites for dopaminergic neurons in the midbrain and forebrain (Ye *et al.*, *Cell* 93:755-766 (1998)). In addition, Nurr1, an orphan receptor belonging to the nuclear  
15 receptor superfamily (Law *et al.*, *Mol. Endocrinol.* 6:2192-2135 (1992) and Zetterstrom *et al.*, *Mol. Endocrinol.* 10:1656-1666 (1996)), and the bicoid-related homeobox factor Ptx3/Pitx3 (Semina *et al.*, *Human Mol. Genet.* 6:2109-2116 (1997); Semina *et al.*, *Nature Genet.* 19:167-170 (1998); and Smidt *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13305-13310 (1997)) appear to be involved in midbrain dopaminergic  
20 determination.

Briefly, Nurr1 is expressed at embryonic day (E) 10.5 in the ventral aspect of the mesencephalic flexure and continues to be expressed into adulthood (Zetterstrom *et al.*, *Mol. Endocrinol.* 10:1656-1666 (1996) and Zetterstrom *et al.*, *Mol. Brain Res.* 41:111-120 (1996)). Ptx3 is expressed in ventral midbrain starting at E11.5, soon  
25 after Nurr1 begins to be expressed (Smidt *et al.*, *Proc. Natl. Acad. Sci. USA* 94:13305-13310 (1997) and Saucedo-Cawdenas *et al.*, *Proc. Natl. Acad. Sci. USA* 95:4013-4018 (1998)). Nurr1-null mice lack midbrain dopaminergic neurons and die within 24 h after birth (Zetterstrom *et al.*, *Science* 276:248-250 (1997); Saucedo-Cawdenas *et al.*, *Proc. Natl. Acad. Sci. USA* 95:4013-4018 (1998); and Castillo *et al.*, *Mol. Cell.*  
30 *Neurosci.* 11:36-46 (1998)). In addition, dopamine is absent in the substantia nigra

and ventral tegmental area of Nurr1-null mice (Castillo *et al.*, *Mol. Cell. Neurosci.* 11:36-46 (1998)). However, TH immunoreactivity and mRNA expression in hypothalamic, olfactory, and lower brain stem regions were unaffected, and DOPA treatments, whether given to the pregnant dams or to the newborns, failed to rescue the Nurr1-null mice (Castillo *et al.*, *Mol. Cell. Neurosci.* 11:36-46 (1998)).

### SUMMARY

The present invention relates to the regulation of tyrosine hydroxylase expression and treatment of catecholamine-related diseases. Specifically, the invention provides cells that contain exogenous nucleic acid having a nucleic acid sequence that encodes Nurr1 (SEQ ID NO:2) as well as methods and materials for inducing tyrosine hydroxylase expression, treating catecholamine-related deficiencies, and identifying tyrosine hydroxylase-related deficiencies.

The present invention is based on the discovery that expression of Nurr1 polypeptide induces tyrosine hydroxylase expression in cells derived from an adult mammal. Specifically, expression of Nurr1 polypeptide induces TH expression in both differentiated and undifferentiated adult rat-derived hippocampal progenitor cells (AHPs). In addition, AHPs overexpressing Nurr1 can produce elevated levels of DOPA and DOPAC, indicating that the TH expression induced by Nurr1 expression results in functional TH enzyme.

The present invention also is based on the discovery that Nurr1 polypeptide induces tyrosine hydroxylase expression by binding directly to the TH promoter. Specifically, Nurr1 polypeptide was found to bind directly to the TH promoter region at positions -873 to -866 (5'-AAAGGTCA-3'). Since mutations within this Nurr1-binding element of the tyrosine hydroxylase promoter region can result in reduced reporter gene expression and thus tyrosine hydroxylase-related deficiencies, such deficiencies can be identified by assessing the nucleic acid sequence within the TH promoter. Clearly, identifying a tyrosine hydroxylase-related deficiency within a mammal can provide useful information for directing medical practitioners to appropriate treatments.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present

5 invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

10 Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

### DESCRIPTION OF DRAWINGS

Figure 1 is a diagram depicting the expression of the indicated transcripts by  
15 HC7 and C31 cells under proliferation (FGF-2+) and various differentiation (FGF-2-) conditions. Total RNA isolated from rat brain E13.5 was used as control.

Figure 2 is a diagram depicting the NIT, GIT, and RVEN3 retroviral vectors.

Figure 3 is a diagram depicting the expression of the indicated transcripts by cells expressing Shh-N. Column a, RT-PCR products generated from total RNA  
20 isolated from differentiated (FGF-2 withdrawal followed by 6 days of RA treatment) C31 cells that were infected 24 hours before triggering differentiation with retroviral vectors expressing either GFP or Shh-N. Column b, RT-PCR products generated from total RNA isolated from differentiated (FGF-2 withdrawal followed by 6 days of RA treatment), stable HC7-GFP or HC7-Shh-N cells that were treated with  
25 tetracycline until just before differentiation. Column c, RT-PCR products generated from total RNA isolated from differentiated (FGF-2 withdrawal followed by 6 days of FK treatment), stable HC7-GFP or HC7-Shh-N cells that were cultured without tetracycline for 10 days before differentiation. Column d, RT-PCR products generated from total RNA isolated from differentiated (FGF-2 withdrawal followed by 6 days of  
30 RA treatment), stable HC7-GFP or HC7-Shh-N cells that were cultured without

tetracycline for ten days before differentiation.

Figure 4 a, b, and c is a diagram depicting the expression of the indicated transcripts by HC7 cells forced to express GFP, Shh-N, Nurr1, or Nurr1a stably and HC7-Nurr1 cells forced to express GFP or Ptx3 transiently. RT-PCR products were  
5 generated from total RNA isolated from cells that were proliferating in the absence of tetracycline for two days.

Figure 5 is a diagram depicting the expression of TH by HC7-Nurr1 cells cultured in the indicated condition for 24 hours. FGF-2+ indicates proliferating conditions, and FGF-2- indicates differentiating conditions triggered by FGF-2  
10 withdrawal.

Figure 6 is a diagram depicting the expression of the indicated transcripts by various cells. Panel A, RT-PCR products generated from total RNA isolated from C31 cells infected with retroviruses (RVEN3) expressing GFP, Shh-N, Nurr1, or Nurr1a transiently, and induced immediately to differentiate in the presence of RA.  
15 Panel B, RT-PCR products generated from total RNA isolated from HC7 cells infected with retroviruses (NIT) expressing GFP, Shh-N, Nurr1, or Nurr1a, selected in G418 for ten days without tetracycline, and induced to differentiate in the presence of RA. Panel C, RT-PCR products generated from total RNA isolated from HC7 cells infected with retroviruses (NIT) expressing GFP, Shh-N, Nurr1, or Nurr1a, selected in  
20 G418 for ten days without tetracycline, and induced to differentiate in the presence of FK. Nurr1/Ptx3 cells represents stable HC7-Nurr1 cells transiently expressing Ptx3.

Figure 7 contains three HPLC chromatograms. Panel A, HPLC chromatogram of a cell lysate from HC7 cells propagated with FGF-2. Panel B, HPLC chromatogram of a cell lysate from HC7-Nurr1 cells differentiated in the presence of  
25 FK. Panel C, HPLC chromatogram of the same cell lysate of Panel B spiked with a mix of DOPA, dopamine (DA), and DOPAC (50 ng/ml).

### DETAILED DESCRIPTION

The invention provides methods and materials related to the regulation of  
30 tyrosine hydroxylase expression as well as the treatment of catecholamine-related

diseases. Specifically, the invention provides cells that contain exogenous nucleic acid as well as methods and materials for inducing tyrosine hydroxylase expression, treating catecholamine-related deficiencies, and identifying tyrosine hydroxylase-related deficiencies.

5           Cells containing exogenous nucleic acid that encodes Nurr1 are clinically useful, providing medical practitioners with biological material that can produce elevated levels of particular predetermined compounds such as DOPA, dopamine, norepinephrine, and DOPAC. Such cells containing exogenous Nurr1 nucleic acid can express Nurr1 polypeptide that induces TH enzyme synthesis that, in turn, results  
10 in the conversion of tyrosine into DOPA. The particular compound produced by a cell containing the exogenous Nurr1 nucleic acid can be determined based upon the set of enzymes, in addition to TH, that are expressed by that cell. For example, cells that express little to no AADC and contain exogenous Nurr1 nucleic acid can synthesize and accumulate DOPA, while cells that express AADC and DBH, and  
15 contain exogenous Nurr1 nucleic acid can synthesize and accumulate norepinephrine.

          In addition, cells expressing Nurr1, and thus functional TH enzyme resulting in catecholamine production, can be used to treat catecholamine-related deficiencies associated with disease states such as Parkinson's disease, manic depression, and schizophrenia. For example, cells containing exogenous Nurr1 nucleic acid can be  
20 administered (e.g., intracranial injection) to the substantia nigra region of a Parkinson's disease patient such that those cells provide that region of the brain with dopamine. Clearly, the induction of tyrosine hydroxylase expression in a cell using an exogenous nucleic acid that encodes Nurr1 is a useful means for creating catecholamine-producing cells that can be used in the medical treatment of  
25 catecholamine-related deficiencies.

          In a first embodiment, the invention provides cells containing an exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the rat Nurr1 amino acid sequence (Table 1; SEQ ID NOs:1 and 2). Such cells are included within the scope of the invention  
30 provided the encoded amino acid sequence is expressed and induces tyrosine



hydroxylase expression in that cell. Such cells include, without limitation, neural progenitor cells, neural cells, and neural stem cells. In addition, such cells may express midbrain markers such as Otx1 and En1, midbrain dopaminergic markers such as Ptx3, and any other polypeptide such as those associated with neurons and synaptic transmission. For example, a cell within the scope of the invention expresses vesicular monoamine transporters (e.g., VAMT1 and VMAT2), synaptotagmins, syntaxin, and/or synaptobrevin.

Table 1. Nucleic acid and amino acid sequence of rat Nurr1 (SEQ ID NOs:1 and 2).

10 atgccttggtgttcagggcgcagtatgggtcctcgctcaaggagccagcccccgttctcag  
agctacagttaccactcttcgggagaatacagctccgatttcttaactccagagtttgtc  
aagtttagcatggacctcaccaacactgaaattactgccaccacttctctccccagcttc  
agtacctttatggacaactacagcacaggctacgacgtcaagccaccttgcttgtaacaa  
atgccccctgtccggacagcagtcctccattaaggtagaagacattcagatgcacaactac  
15 cagcaacacagccacctgccccctcagtcaggagatgatgccacacagcgggtcggtt  
tactacaagccctcttcgcccccgacacccagcaccgccgggttccaggtgcagcatagc  
ccgatgtgggacgatccgggtcccttcacaacttcaccagaactacgtggccactacg  
catatgatcgagcagaggaagacacctgtctccgcctttcactcttctcctttaagcag  
tcgcccccgggcactcctgtgtctagctgccagatgcgctttgacgggcctctgcacgtc  
20 cccatgaacccggagcccggggcagccaccacgtactggatgggcagaccttcgccgtg  
cccaatcccattcgcaagccggcatccatgggttcccgggcctgcagatcggccacgcg  
tcgcagttgcttgacacgcaggtgccctcgccgcgtcccGggctctccctccaatgag  
ggtctgtgcgctgtttgcggtgacaacgcggcctgtcagcattacgggtgttcgcaottgt  
gagggctgcaaagggttctttaagcgcacgggtgcaaaaaaacgcgaaatatgtgtgttta  
25 gcaataaaaaattgccagtggtataagcgcggccgaaatcggtgtcagtagtgcggtt  
cagaagtgcctggctgttgggatggttaaagaagtgggttcgcacggacagtttaaaaggc  
cggagaggtcgtctaccctcaaaaccgaagagccacaggatccccctctccccctcacct  
ccggtgagctctgatcagtgccctcgtcagagcccacgtcgactccaatccggcaatgacc  
agcctggactattccaggttccaggcaaacctgactatcagatgagtgagatgatact  
30 caacatatccagcagttctacgatctcctgactggctctatggagatcatcagaggggtg  
gcagagaagattcctggctttgctgacctgccccaaagccgatcaggacctgcttttgaa  
tcagcttcttagaattatttgttctacgcttagcatacaggtccaaccagtgagggt

aaactcatcttttgcaatggggtggtcttgacaggttgcaatgcgtgcgtggctttggg  
 gaatggattgattccattggtgaattctcctccaacttgagaatatgaacatcgacatt  
 tctgccttctcctgcattgctgcccctggctatggtcacagagagacacgggctcaaggaa  
 cccaagagagtggagagctacaaaacaaattgtaaattgtcttaaagaccatgtgact  
 5 ttcaataatgggggattgaaccgacccaactacctgtccaaactgttggggaagctccca  
 gaacttcgcaccctttgcacacaggggctccagcgcatcttctacctgaaattggaagac  
 ttggtaccaccaccagcaataattgacaaacttttcttgacaccttacctttctaa

MPCVQAQYGSSPQGASPASQSYSHSSGEYSSDFLTPEFVKFSMDLTNTEITATTSLSF  
 10 STFMDNYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQMNHYQQHSHLPPQSEEMPHSGSV  
 YYKPSSPPTPSTPGFQVQHSPMWDDPGSLHNFHQNYVATTHMIEQRKTPVSRLSLFSFKQ  
 SPPGTPVSSQMRFDGPLHVPMPNPEPAGSHHVVDGQTFVNPPIRKPASMGFPGLQIGHA  
 SQLLDTQVPSPPSRGSPSNEGLCAVCGDNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCL

15 The term "progenitor cell" as used herein refers to any cell that can give rise to  
 a distinct cell lineage through cell division. In other words, progenitor cells can be  
 generally described as cells that give rise to differentiated cells. For example, a neural  
 progenitor cell is a parent cell that can give rise to a daughter cell having  
 characteristics similar to a neural cell. The term "neural cell" as used herein refers to  
 20 neurons, including dopaminergic neurons as well as glial cells, including astrocytes,  
 oligodendrocytes, and microglia. For the purpose of this invention, all neuroepithelial  
 cells of the diencephalon, telencephalon, mesencephalon, myelencephalon, and  
 metencephalon as well as adult hippocampal progenitor cells (AHPs), adult  
 subventricular zone stem cells, and adult spinal cord progenitor are considered to be  
 25 neural progenitor cells. In addition, all neuroepithelial cells of the mesencephalon as  
 well as AHPs, are considered to be midbrain neural progenitor cells. Moreover, a cell  
 within the scope of the invention can be a mammalian cell. For example, mammalian  
 cells derived from a mammal at any stage of development from blastula formation to  
 adult can contain an exogenous nucleic acid.

30 The term "nucleic acid" as used herein encompasses both RNA and DNA,  
 including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA.

The nucleic acid can be double-stranded or single-stranded. Where single-stranded, the nucleic acid can be the sense strand or the antisense strand. In addition, nucleic acid can be circular or linear.

The term "exogenous" as used herein with reference to nucleic acid and a particular cell refers to any nucleic acid that does not originate from that particular cell as found in nature. Thus, all non-naturally occurring nucleic acid are considered to be exogenous to a cell once introduced into the cell. It is important to note that non-naturally occurring nucleic acid can contain nucleic acid sequences or fragments of nucleic acid sequences that are found in nature provided the nucleic acid as a whole does not exist in nature. For example, a nucleic acid containing a genomic DNA sequence within an expression vector is considered to be a non-naturally occurring nucleic acid, and thus is considered to be exogenous to a cell once introduced into the cell, since that nucleic acid as a whole (genomic DNA plus vector DNA) does not exist in nature. Thus, any vector, autonomously replicating plasmid, or virus (e.g., retrovirus, adenovirus, or herpes virus) that as a whole do not exist in nature is considered to be a non-naturally-occurring nucleic acid. It follows that genomic DNA fragments produced by PCR or restriction endonuclease treatment as well as cDNA's are considered to be a non-naturally-occurring nucleic acid since they exist as separate molecules not found in nature. It also follows that any nucleic acid containing a promoter sequence and polypeptide-encoding sequence (e.g., cDNA or genomic DNA) in an arrangement not found in nature is considered to be a non-naturally occurring nucleic acid.

It is also important to note that a nucleic acid that is naturally occurring can be exogenous to a particular cell. For example, an entire chromosome isolated from a cell of person X would be considered an exogenous nucleic acid with respect to a cell of person Y once that chromosome is introduced into Y's cell.

Nucleic acid that is considered to be exogenous to a particular cell can be obtained using common molecular cloning or chemical nucleic acid synthesis procedures and techniques, including PCR. PCR refers to a procedure or technique in which target nucleic acid is amplified in a manner similar to that described in U.S.

Patent No. 4,683,195, and subsequent modifications of the procedure described therein. Generally, sequence information from the ends of the region of interest or beyond are used to design oligonucleotide primers that are identical or similar in sequence to opposite strands of a potential template to be amplified. Using PCR, a nucleic acid sequence can be amplified from RNA or DNA. For example, a nucleic acid sequence can be isolated by PCR amplification from total cellular RNA, total genomic DNA, and cDNA as well as from bacteriophage sequences, plasmid sequences, viral sequences, and the like. When using RNA as a source of template, reverse transcriptase can be used to synthesize complimentary DNA strands.

Standard nucleic acid sequencing techniques and software programs that translate nucleic acid sequences into amino acid sequences based on the genetic code can be used to determine whether or not a particular nucleic acid has a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2. For the purpose of this invention, the percent amino acid sequence identity between the sequence set forth in SEQ ID NO:2 and any other amino acid sequence is calculated as follows. First, the two amino acid sequences are aligned using the MEGALIGN<sup>®</sup> (DNASTAR, Madison, WI, 1997) sequence alignment software following the Jotun Heim algorithm with the default settings. Second, the number of matched positions between the two aligned amino acid sequences is determined. A matched position refers to a position in which identical residues occur at the same position as aligned by the MEGALIGN<sup>®</sup> sequence alignment software. Third, the number of matched positions is divided by 598, and the resulting value multiplied by 100 to obtain the percent identity. If the obtained percent identity is greater than or equal to 65 for a particular amino acid sequence, then that particular amino acid sequence is an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2.

Nucleic acid having a nucleic acid sequence that encodes a polypeptide having an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2 can be identified and obtained using any method. For example, the nucleic acid sequence set forth in SEQ ID NO:1 can be mutated using common molecular cloning techniques (e.g., site-directed mutageneses) such that the amino acid sequence

encoded by the mutated nucleic acid sequence is at least 65 percent identical to the sequence set forth in SEQ ID NO:2. Possible mutations include, without limitation, deletions, insertions, and base substitutions, as well as combinations of deletions, insertions, and base substitutions. In addition, nucleic acid and amino acid databases (e.g., GenBank<sup>®</sup>) can be used to identify a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2. Briefly, any amino acid sequence having some homology to the sequence set forth in SEQ ID NO:2, or any nucleic acid sequence having some homology to the sequence set forth in SEQ ID NO:1 can be used as a query to search GenBank<sup>®</sup>.

Search results then can be analyzed to determine the percent identity between the amino acid sequences obtained from an amino acid search, or the encoded amino acid sequences obtained from a nucleic acid search, and the amino acid sequence set forth in SEQ ID NO:2.

Further, PCR and nucleic acid hybridization techniques can be used to identify nucleic acid having a nucleic acid sequence that encodes a polypeptide having an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2. Briefly, any nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2, or fragment thereof, can be used as a probe to identify a similar nucleic acid by hybridization under conditions of moderate to high stringency. Such similar nucleic acid then can be isolated, sequenced, and analyzed to determine the percent identity between the encoded amino acid sequences and the amino acid sequence set forth in SEQ ID NO:2.

In general, high stringency conditions can be used to identify nucleic acid having a high degree of homology to a probe. High stringency conditions can include the use of a denaturing agent such as formamide during hybridization, e.g., 50% formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, and 75 mM sodium citrate at 42°C. Another example is the use of 50% formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.5),

0.1% sodium pyrophosphate, 5X Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% sodium lauryl sulfate (SDS), and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2X SSC and 0.1% SDS. Alternatively, low ionic strength and high temperature can be used for washing, for example, 0.1X SSC (0.015 M NaCl/0.0015 M sodium citrate), 0.1% SDS at 65°C.

Moderate stringency conditions can be used to identify nucleic acid having a moderate degree of homology to a probe. Moderate stringency conditions can include the use of higher ionic strength and/or lower temperatures for washing of the hybridization membrane, compared to the ionic strength and temperatures used for high stringency hybridization. For example, a wash solution of 4X SSC (0.06 M NaCl/0.006 M sodium citrate), 0.1% SDS can be used at 50°C, with a last wash in 1X SSC at 65°C. Alternatively, a hybridization wash in 1X SSC at 37°C can be used.

Low stringency conditions can be used to identify nucleic acid having a low degree of homology to a probe. Low stringency conditions can include the use of higher ionic strength and/or lower temperatures for washing of the hybridization membrane, compared to the ionic strength and temperatures used for moderate stringency hybridization. For example, a wash solution of 4X SSC (0.06 M NaCl/0.006 M sodium citrate), 0.1% SDS can be used at 37°C, with a last wash in 1X SSC at 45°C. Alternatively, a hybridization wash in 2X SSC at 37°C can be used.

Hybridization can be done by Southern or Northern analysis to identify a DNA or RNA sequence, respectively, that hybridizes to a probe. The probe can be labeled with a radioisotope such as <sup>32</sup>P, an enzyme, digoxigenin, or by biotinylation. The DNA or RNA to be analyzed can be electrophoretically separated on an agarose or polyacrylamide gel, transferred to nitrocellulose, nylon, or other suitable membrane, and hybridized with the probe using standard techniques well known in the art such as those described in sections 7.39-7.52 of Sambrook *et al.*, (1989) Molecular Cloning, second edition, Cold Spring harbor Laboratory, Plainview, NY. Typically, a probe is at least about 20 nucleotides in length. For example, a probe corresponding to a 20 nucleotide sequence within SEQ ID NO:1 can be used to identify a nucleic acid identical to or similar to the nucleic acid sequence of SEQ ID NO:1. In addition,

probes longer or shorter than 20 nucleotides can be used.

As described herein, the cells of the invention must not only contain an exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2, but  
5 must also express the encoded amino acid sequence such that tyrosine hydroxylase expression is induced. Methods of identifying cells that contain exogenous nucleic acid are well known to those skilled in the art. Such methods include, without limitation, PCR and nucleic acid hybridization techniques such as Northern and Southern analysis. In some cases, immunohistochemistry and biochemical techniques  
10 can be used to determine if a cell contains a particular nucleic acid by detecting the expression of a polypeptide encoded by that particular nucleic acid. For example, detection of Nurr1-immunoreactivity after introduction of an exogenous nucleic acid containing a cDNA that encodes Nurr1 into a cell that does not normally express Nurr1 polypeptide can indicate that that cell not only contains the introduced  
15 exogenous nucleic acid but also expresses the encoded Nurr1 polypeptide from that introduced exogenous nucleic acid. In this case, the detection of Nurr1 induced TH expression (e.g., increases in TH mRNA levels, TH-immunoreactivity, or TH enzymatic activity) also can indicate that that cell contains the introduced exogenous nucleic acid and expresses the encoded Nurr1 polypeptide from that introduced  
20 exogenous nucleic acid.

In addition, methods for expressing an amino acid sequence from an exogenous nucleic acid are well known to those skilled in the art. Such methods include, without limitation, constructing a nucleic acid such that a regulatory element promotes the expression of a nucleic acid sequence that encodes a polypeptide.  
25 Typically, regulatory elements are DNA sequences that regulate the expression of other DNA sequences at the level of transcription. Thus, regulatory elements include, without limitation, promoters, enhancers; and the like.

Methods of identifying cells that express an amino acid sequence from an exogenous nucleic acid also are well known to those skilled in the art. Such methods  
30 include, without limitation, immunocytochemistry, Northern analysis, and RT-PCR.

Likewise, the expression of tyrosine hydroxylase can be determined using immunocytochemistry, Northern analysis, or RT-PCR, for example. Briefly, immunocytochemistry using anti-TH antibodies can be used to assess the expression of TH polypeptide, while Northern analysis and RT-PCR techniques can be used to  
5 assess the expression of TH mRNA. Any increased expression of TH polypeptide or TH mRNA attributed to the expression of the amino acid sequence encoded by the exogenous nucleic acid is considered to be the induced TH expression. A simple comparison between TH expression results obtained from appropriate cells with and without the exogenous nucleic acid can be used to determine increases in TH  
10 expression. It is also noted that TH expression can be assessed using HPLC to measure the amount of DOPA, dopamine, norepinephrine, or DOPAC within cells, since the amount of these compounds within a cell can correlate with the expression of TH polypeptide.

The exogenous nucleic acid contained within a cell of the invention can be  
15 maintained within that cell in any form. For example, exogenous nucleic acid can be integrated into the genome of the cell or maintained in an episomal state. In other words, a cell of the invention can be a stable or transient transformant.

Any method can be used to introduce an exogenous nucleic acid into a cell. In fact, many methods for introducing nucleic acid into cells, whether *in vivo* or *in vitro*,  
20 are well known to those skilled in the art. For example, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and viral-mediated nucleic acid transfer are common methods for introducing nucleic acid into cells. In addition, naked DNA can be delivered directly to cells *in vivo* as describe elsewhere (U.S. Patent Number 5,580,859 and U.S. Patent Number 5,589,466  
25 including continuations thereof). Further, nucleic acid can be introduced into cells by generating transgenic animals.



Transgenic animals can be aquatic animals (such as fish, sharks, dolphin, and the like), farm animals (such as pigs, goats, sheep, cows, horses, rabbits, and the like), rodents (such as rats, guinea pigs, and mice), non-human primates (such as baboon, monkeys, and chimpanzees), and domestic animals (such as dogs and cats). Several techniques known in the art can be used to introduce nucleic acid into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (U.S. Patent No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten *et al.*, *Proc. Natl. Acad. Sci., USA*, 82:6148-6152 (1985)); gene transfection into embryonic stem cells (Gossler A *et al.*, *Proc Natl Acad Sci USA* 83:9065-9069 (1986)); gene targeting into embryonic stem cells (Thompson *et al.*, *Cell*, 56:313-321 (1989)); nuclear transfer of somatic nuclei (Schnieke AE *et al.*, *Science* 278:2130-2133 (1997)); and electroporation of embryos.

For a review of techniques that can be used to generate and assess transgenic animals, skilled artisans can consult Gordon (*Intl. Rev. Cytol.*, 115:171-229 (1989)), and may obtain additional guidance from, for example: Hogan *et al.*, "Manipulating the Mouse Embryo" Cold Spring Harbor Press, Cold Spring Harbor, NY (1986); Krimpenfort *et al.*, *Bio/Technology*, 9:844-847 (1991); Palmiter *et al.*, *Cell*, 41:343-345 (1985); Kraemer *et al.*, "Genetic Manipulation of the Early Mammalian Embryo" Cold Spring Harbor Press, Cold Spring Harbor, NY (1985); Hammer *et al.*, *Nature*, 315:680-683 (1985); Purscel *et al.*, *Science*, 244:1281-1288 (1986); Wagner *et al.*, U.S. Patent No. 5,175,385; and Krimpenfort *et al.*, U.S. Patent No. 5,175,384.

#### *Methods for inducing TH expression*

As described herein, TH expression can be induced in a cell by providing a cell with an exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2 such that the encoded amino acid sequence is expressed. In addition, any method including those described herein can be used to introduce such an exogenous nucleic acid into a cell.

Further, a kit containing a proliferation factor and nucleic acid having a nucleic

acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2 can be used to induce tyrosine hydroxylase expression in a cell (e.g., AHPs). A proliferation factor is any polypeptide that promotes the proliferation of cells in tissue culture including, without limitation, FGF-2, FGF-4, and EGF. The proliferation factor can be used to maintain cells in a proliferative state while the nucleic acid is being introduced into the cells.

#### *Treating catecholamine-related deficiencies*

Catecholamine-related deficiencies in a mammal (e.g., a human patient) can be treated by administering an effective amount of cells to a mammal. The administered cells contain, as described herein, exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2 such that the encoded amino acid sequence is expressed and induces tyrosine hydroxylase expression. This induced TH expression causes the cells to produce a catecholamine such as dopamine or norepinephrine.

A catecholamine-related deficiency is any physical or mental condition that is associated with or attributed to an abnormal level of a catecholamine such as dopamine or norepinephrine. This abnormal level of catecholamine can be restricted to a particular region of the mammal's brain (e.g., midbrain) or adrenal gland. A catecholamine-related deficiency can be associated with disease states such as Parkinson's disease, manic depression, and schizophrenia. In addition, catecholamine-related deficiencies can be identified using clinical diagnostic procedures.

An effective amount of cells is any amount that does not cause significant toxicity to the mammal and results in either the production of a more normal level of a catecholamine or a relief, to at least some degree, of at least one clinical symptom associated with the catecholamine-related deficiency. Such an amount can be determined by assessing the clinical symptoms associated with the catecholamine-related deficiency before and after administering a fixed amount of cells. In addition, the effective amount of cells administered to a mammal can be adjusted according to the mammal's response and desired outcomes. Significant toxicity can vary for each particular patient and depends on multiple factors including, without limitation, the

patient's physical and mental state, age, and tolerance to pain. The cells can be administered to any part of the mammal's body including, without limitation, midbrain, brainstem, and adrenal gland.

Catecholamine-related deficiencies also can be treated by administering an exogenous nucleic acid to a cell of the mammal. The administration can be an *in vivo*, *in vitro*, or *ex vivo* administration as described herein. For example, an *in vivo* administration can involve administering a viral vector to the midbrain region of a mammal, while an *ex vivo* administration can involve extracting midbrain cells from a mammal, transfecting the cells with an exogenous nucleic acid in tissue culture, and then introducing the transfected cells back into the same mammal.

#### *Identifying TH-related deficiencies*

A tyrosine hydroxylase-related deficiency is any physiological condition characterized by a reduced level of TH expression within a cell or group of cells. Tyrosine hydroxylase-related deficiencies can be associated with disease states such as Parkinson's disease, manic depression, and schizophrenia. In addition, such deficiencies can be identified by assessing the nucleic acid sequence of Nurr1-binding elements located in the TH promoter. A Nurr1-binding element is a portion of DNA that Nurr1 polypeptide binds directly. For example, a Nurr1-binding element can be located in the TH promoter region at positions -873 to -866 and can have a nucleic acid sequence as set forth in this sequence 5'-AAAGGTCA-3'. Common molecular biology techniques can be used to assess the nucleic acid within the -873 to -866 region of the TH promoter for the presence or absence or mutation of this 5'-AAAGGTCA-3' sequence. For example, genomic DNA can be isolated from cells collected from a mammal and a fragment of DNA containing the -873 to -866 region of the TH promoter amplified by PCR. Once amplified, the -873 to -866 region can be sequenced and any changes to the 5'-AAAGGTCA-3' sequence determined. Murphy *et al.*, *Gene Expression*, Vol. 5, 169-179 (1996). For example, AAAGGTCA mutation in the two underlined positions permits neural binding.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

## EXAMPLES

### Example 1 - Differentiation of adult neural progenitor cells into midbrain dopaminergic neuronal phenotype

The following experimental procedures were used to isolate and propagate rat adult hippocampal progenitor cells (AHPs). Briefly, neural precursors from adult rat hippocampal formations were isolated in culture as described elsewhere (Gage *et al.*, *Proc. Natl. Acad. Sci USA* 92:11879-1188 (1995)). Primary cultures were maintained on laminin coated dishes as described by Ray *et al.* (*Proc. Natl. Acad. Sci. USA* 90:3602-3606 (1993)) using DMEM:F12 (1:1) media supplemented with N2 supplement (GIBCO) and 20 ng/ml recombinant human FGF-2 from E. coli (provided by A. Baird. The bulk population of AHPs designated HC7 herein have been characterized elsewhere (Palmer *et al.*, *Mol. Cell. Neurosci.* 8:389-404 (1997)). The HC7 cells were used at passages 10 through 20. The stem cell-derived clone designated C31 was isolated from the HC7 population. These cells have also been described elsewhere (Palmer *et al.*, *Mol. Cell. Neurosci.* 8:389-404 (1997)). Both polyclonal (HC7) and clonal (C31) populations can generate a variety of neuronal phenotypes including GABA, TH, and AChE-positive neurons.

To induce differentiation, cells were initially plated onto laminin coated 6 cm dishes or coated chamber slides at a density of  $2 \times 10^4$  or  $10^5$  cells per  $\text{cm}^2$ , respectively. Cells were allowed to proliferate in N2 supplemented medium containing 20 ng/ml FGF-2 for 24 hours. FGF-2 was then withdrawn and the cells subsequently treated with N2 medium alone or with N2 medium containing 0.5  $\mu\text{M}$  retinoic acid (RA), 5  $\mu\text{M}$  forskolin (FK), or 40 ng/ml FGF-8. Medium was replaced every 48 hours.

The expression of A-P and D-V markers by the fibroblast growth factor-2 (FGF-2)-responsive AHPs was examined using RT-PCR as follows. Briefly, total RNA was isolated from cell culture using RNazol (Tel Test). Using the Superscript preamplification system (GIBCO BRL), cDNA was made from 4  $\mu\text{g}$  of total RNA. First strand cDNA was diluted 3-fold, and 2  $\mu\text{l}$  of the diluted cDNA used for each PCR reaction. RT-PCR products were analyzed in a 1.5% agarose gel containing

Ethidium Bromide (EtBr). DNA bands were photographed using an Eagle Eye XI video system (Stratagene). The image was exported in a TIFF file and DNA bands were quantified using NIH Image 1.55 software for Macintosh. The quantification value of the band was designated the absorbance (Pixels). Measurements of

5 absorbance using the above system were linear up to 120 pixels. For quantitative PCR, cycle numbers and template quantity were determined to be in the linear range for each gene. Kinetic analyses were also used to demonstrate linearity as described elsewhere (Yokoi *et al.*, *Biophys. Res. Commun.* 195:769-775 (1993)). Regression equations of the form:  $Y=A \times E^n$ , where Y is the yield of PCR products, E is the

10 efficiency of amplification, and n is the number of cycles, were fitted to the data in the linear portion of the semilogarithmic graphs. The coefficient A was calculated for each reaction in order to estimate the relative amount of mRNA. Each sample was analyzed at least three times, and the difference in the obtained values was always less than 2%. For each experimental test condition, at least two independent experiments

15 were performed. The following primers were used to amplify the indicated target cDNA:

G3PDH: 5'-ACCACAGTCCATGCCATCAC-3' (SEQ ID NO:3)  
and 5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO:4)

20 TH: 5'-CCTCCTTGTCTCGGGCTGTAA-3' (SEQ ID NO:5)  
and 5'-CTGAGCTTGTCTTGGCGTCA-3' (SEQ ID NO:6)

AADC: 5'-CCTACTGGCTGCTCGGACTAA-3' (SEQ ID NO:7)  
and 5'-GCGTACCAGGGACTCAAACCTC-3' (SEQ ID NO:8)

DBH: 5'-GTGACCAGAAAGGGCAGATCC-3' (SEQ ID NO:9)  
25 and 5'-CACCGGCTTCTTCTGGGTAGT-3' (SEQ ID NO:10)

GFAP: 5'-GCAGACCTCACAGACGTTGCT-3' (SEQ ID NO:11)  
and 5'-AGGCTGGTTTCTCGGATCTGG-3' (SEQ ID NO:12)

Phox2A: 5'-TGGCGCTCAAGATCGACCTCA-3' (SEQ ID NO:13)  
and 5'-CGTTAGGGTGGGATTAGCGGT-3' (SEQ ID NO:14)

30 Nurr1: 5'-TAAAAGGCCGGAGAGGTCGTC-3' (SEQ ID NO:15)

- and 5'-CTCTCTTGGGTTTCCTTGAGCC-3' (SEQ ID NO:16)
- Ptc: 5'-ACCTTTGGACTGCTTCTGGG-3' (SEQ ID NO:17)  
and 5'-AGTCGTAGCCCCTGAAGTGTT-3' (SEQ ID NO:18)
- Smo: 5'-GCCACCCTGCTCATCTGGA-3' (SEQ ID NO:19)
- 5 and 5'-TTCCGGCCTAAACGCTTCTC-3' (SEQ ID NO:20)
- Gli1: 5'-CATGTGTGAGCAAGAAGGTTGC-3' (SEQ ID NO:21)  
and 5'-AAGTCGAGGACACTGGCTATAGG-3' (SEQ ID NO:22)
- Shh: 5'-TTCTGGTGGCCCTTGCTTCCT-3' (SEQ ID NO:23)  
and 5'-TACTTGCTGCGGTCCCTGTCA-3' (SEQ ID NO:24)
- 10 Otx: 5'-MGIMGIGARMGLIACITTYAC-3' (SEQ ID NO:25)\*  
and 5'-ICKICKRTTIBWRAACCAIACYTG-3' (SEQ ID NO:26)\*
- En: 5'-AARMGICCIMGLIACIGCITTYAC-3' (SEQ ID NO:27)\*  
and 5'-CKYTTRTTYTGRAACCADATYTT-3' (SEQ ID NO:28)\*
- Hox: 5'-YTIGARAARGARTTYCAYTTYAA-3' (SEQ ID NO:29)\*
- 15 and 5'-TTCATICKICKRTTYTGRAACCA-3' (SEQ ID NO:30)\*
- Pax: 5'-MGIMGIWSIMGLIACIACITTYAC-3' (SEQ ID NO:31)\*  
and 5'-ICKICKRTTIBWRAACCAIACYTG-3' (SEQ ID NO:32)\*
- D2R: 5'-GCATCCTGAACCTGTGTGCCA-3' (SEQ ID NO:33)  
and 5'-GCAGCATCCTTGAGTGGTGTC-3' (SEQ ID NO:34)
- 20 GFR $\alpha$ -1: 5'-GATTTGCTGATGTCCGCCGAG-3' (SEQ ID NO:35)  
and 5'-AATCAGTCCCGAGTAGGCCAG-3' (SEQ ID NO:36)
- c-Ret: 5'-AGACAGACCCAGGCTTCGCTA-3' (SEQ ID NO:37)  
and 5'-TTTCCGCTGATGCAATGGGCG-3' (SEQ ID NO:38)
- FGFR: 5'-TCNGAGATGGAGRTGATGAA-3' (SEQ ID NO:39)#
- 25 and 5'-CCAAAGTCHGCDATCTTCAT-3' (SEQ ID NO:40)#

Those particular primers marked with an asterisk (\*) are degenerate primers represented by the indicated amino acid sequence. For the primers marked with a pound sign (#), N represents all four bases, R represents A and G, and H represents A,

30 T and C. The PCR products from the Ptc, Otx, En, and Hox reactions were subcloned

into a TOPO-TA vector (Invitrogen) and analyzed by DNA sequencing, while the identity of each product for the remaining PCR reactions was confirmed by restriction enzyme digestion. Controls included total RNA isolated from rat brain E13.5 as well as PCR reactions lacking reverse transcriptase.

- 5 Otx1, En1, GBX2, HoxA1, HoxA2, HoxB2, HoxD3, and HoxD4 mRNA was detected in both non-clonal cultures (HC7) and stem cell-derived clonal cultures (C31) proliferating in the presence of FGF-2 (Table 2, Figure 1). The broad range of homeobox members present indicates that AHPs are not restricted to the forebrain-specific A-P identities expected for hippocampus-derived cells. Sonic hedgehog (Shh) transcripts were not detected; however, transcripts for the Shh receptors Ptc and Smo, and the Shh-responsive gene Gli1 were detectable in proliferating cells, suggesting some level of Shh-related signal transduction (Figure 1). In addition, expression of midbrain (Otx1 and En1) and midbrain dopaminergic markers (Nurr1 and Ptx3) indicated that some of the AHPs may be competent to generate midbrain-specific dopaminergic neurons.

Table 2. Nucleotide and amino acid sequence of homeobox genes expressed in AHPs

Gene	Nucleotide and amino acid sequence
Otx1	CGGCGGGAGCGGACGACGTTTACGCGCTCACAGCTGGACGTGCTC
20	R R E R T T P T R S Q L D V L
	GAGGCGCTGTTCGCAAAGACTCGCTACCCAGACATCTTCATGCGC
	E A L F A K T R Y P D I F M R
	GAGGAGGTGGCTCTCAAGATCAACCTGCCCCGAGTCCAGAGTCCAA
	E E V A L K I N L P E S R V Q
25	GTCTGGTTCAACAACAGCCGCC (SEQ ID NO:41)
	V W F N N S R (SEQ ID NO:42)

En1 AAGCGGCCGCGGACGGCGTTACGGCCGAGCAGCTGCAGAGACTC  
K R P R T A F T A E Q L Q R L  
AAGGCGGAGTTCCAGGCAAACCGCTACATCACGGAGCAGCGGCGA  
K A E F Q A N R Y I T E Q R R  
5 CAGACCCTGGCCCAGGAGCTCAGCCTGAACGAGTCCCAGATCAAG  
Q T L A Q E L S L N E S Q I K  
ATCTGGTTCCAAAACAAGCGA (SEQ ID NO:43)  
I W F Q N K R (SEQ ID NO:44)

10 GBX2 AAGCGGCCGCGGACGGCGTTTACCAGCGAGCAGCTGCTGGAGCTG  
K R P R T A F T S E Q L L E L  
GAGAAGGAATTCCACTGCAAAAAGTACCTCTCCCTGACCGAGCGC  
E K E F H C K K Y L S L T E R  
TCACAGATCGCCCATGCCCTCAAACCTCAGCGAGGTGCAAGTAAAA  
15 S Q I A H A L K L S E V Q V K  
ATATGGTTCCAAAACAAGCGA (SEQ ID NO:45)  
I W F Q N K R (SEQ ID NO:46)

HoxA1 CTGGAGAAGGAGTTCCATTTCACAAGTACCTAACAAGAGCCCCGC  
20 L E K E F H F N K Y L T R A R  
AGGGTGGAGATAGCCGCGTCCCTGCAACTCAATGAGACCCAGGTG  
R V E I A A S L Q L N E T Q V  
AAGATCTGGTTCCAAAACCGC (SEQ ID NO:47)  
K I W F Q N R (SEQ ID NO:48)

25 HoxA2/B2 CTGGAGAAGGAGTTTCATTTCACAAGTACCTGTGCCGGCCGCGG  
L E K E F H F N K Y L C R P R  
CGGGTTGAGATCGCCGCTTGCTGGACCTACCGAAAGGCAGGTG  
R V E I A A L L D L T E R Q V



AAAGTCTGGTTCCAAAACCGC (SEQ ID NO:49)

K V W F Q N R (SEQ ID NO:50)

HoxD3

CTGGAGAAGGAGTTCCATTTCAACCGCTACCTGTGCCGGCCGCGC

5

L E K E F H F N R Y L C R P R

CGCGTGGAGATGGCTAACCTGCTGAACCTCACCGAACGCCAGATC

R V E M A N L L N L T E R Q I

AAGATCTGGTTCCAAAACCGC (SEQ ID NO:51)

K I W F Q N R (SEQ ID NO:52)

10

HoxD4

CTGGAAAAGGAATTTTCATTTTAACAGGTATCTGACCAGGCGCCGT

L E K E F H F N R Y L T R R R

CGGATTGAAATCGCTCACACCCTGTGTCTGTCTGAGCGCCAGATC

R I E I A H T L C L S E R Q I

15

AAGATCTGGTTTCAAAACAAA (SEQ ID NO:53)

K I W F Q N K (SEQ ID NO:54)

- Cell differentiated in the presence of RA or FK also were evaluated by immunofluorescent staining performed as described elsewhere (Gage *et al.*, *Proc. Natl. Acad. Sci USA* 92:11879-1188 (1995)). Briefly, after fixation with 4% paraformaldehyde in PBS, cells were incubated with primary antibodies overnight at 4°C. After removing the primary antibodies, the cells were incubated overnight at 4°C with secondary antibodies (Jackson ImmunoResearch) conjugated to fluorescein isothiocyanate, cyanin-3, or cyanin-5. Primary antibody concentrations were as follows: mouse anti-MAP2ab (monoclonal, Sigma) at 1:500; mouse anti-TH (monoclonal, Boehringer Mannheim) at 1:500; rabbit anti-TH (polyclonal, Eugenetech) at 1:500; and mouse anti-AADC (monoclonal, Sigma) at 1:500. MAP2ab (microtubule-associated protein 2) is a major component of the neuronal cytoskeleton. Labeled cells were visualized using a Bio-Rad MRC1000 confocal

scanning laser microscope and color images were generated using Adobe Photoshop (Adobe System). The total cell numbers were scored using nuclear counterstaining with 4', 6-diamidino-2-phenylindole (DAPI, Sigma). The relative proportions of each cell phenotype were determined by systematic sampling of 40x fields across the length and breadth of each well.

Only a small proportion of the MAP2ab-immunoreactive neurons was double labeled for TH (0.9 +/- 0.3% in the presence of RA and 1.5 +/- 0.4% in the presence of FK). Nearly all cells were immunoreactive for AADC, but none contained detectable DBH. Consistent with the immunofluorescent data, RT-PCR revealed an early upregulation of TH and AADC (at 6 days) in the absence of detectable DBH (Figure 1) or Phox2a mRNA. DBH and Phox2a are specifically expressed in adrenergic neurons. Withdrawal of FGF-2 and treatment with FK also induced a rapid upregulation of Nurr1 mRNA expression (Figure 1). Although RA treatment also stimulated TH expression at both the polypeptide and RNA levels, the coordinated upregulation of Nurr1 and AADC seen with FK was absent. In fact, RA had an inhibitory effect on AADC and Ptx3 mRNA expression (Figure 1), indicating that RA and FK have overlapping yet clearly distinct effects on the signaling cascades leading to a dopaminergic phenotype.

In addition, GFR $\alpha$ -1, a GPI-linked GDNF binding polypeptide, was constitutively expressed under both proliferating and differentiating conditions (Figure 1), and the receptor tyrosine kinase c-Ret, another component of the GDNF receptor, was upregulated in response to FK. Taken together, this RT-PCR data indicates that FK activates a broad transcriptional response consistent with dopaminergic rather than adrenergic or noradrenergic differentiation.

25

Example 2 - FGF-8 does not increase TH expression  
when applied during differentiation

FGFR1, FGFR2, and FGFR3 expression was observed in AHPs, indicating that AHPs may be competent to respond to FGF-8. Since the high concentration of FGF-2 used to propagate AHPs (20 ng/ml) can activate all three FGF receptors (Ornitz *et al.*, *J. Biol. Chem.* 271:15292-15297 (1996)), the effects of exogenously applied FGF-8 might be masked in proliferating cells. Indeed, FGF-8 did not show any obvious effect on TH expression in the presence of FGF-2. FGFR3 expression, however, did increase following FGF-2 withdrawal. Thus, FGF-8 could potentially exhibit a measurable effect following FGF-2 withdrawal during the subsequent differentiation. Interestingly, FGF-8 had little effect on TH, Nurr1, or Ptx3 expression after 4 days, either in the absence or presence of FK. These results indicate that FGFR3 signaling is not important during the terminal stages of differentiation, but may instead be critical in promoting a dopaminergic competence during the early proliferative expansion of precursors. In this case, the high concentrations of FGF-2 used to maintain proliferative cultures could substitute for FGF-8 in promoting dopaminergic competence for AHPs.

Example 3 - Forced expression of Shh-N, Nurr1, Nurr1a, and Ptx3

1. *Cloning of Shh-N, Nurr1, Nurr1a, and Ptx3*

cDNAs containing the full open reading frames of rat Shh-N, Nurr1, Nurr1a, and Ptx3 were cloned by RT-PCR from polyA RNA derived from Fischer 344 rat embryonic brain at embryonic day 13.5. Total RNA was isolated as described by Okayama *et al.* (*Methods Enzymol.* 154:3-28 (1987)). PolyA RNA was purified using Oligo(dT)-cellulose (Pharmacia) column chromatography. First strand cDNA synthesis was carried out using 50 ng of polyA RNA, Superscript II reverse transcriptase (GIBCO BRL), and oligo dT primer followed by RNase H treatment. The resulting products were PCR amplified using Pwo polymerase (Boehringer Mannheim) and the following primers:

	5' primer for Shh-N:	5'-CGTACCAGCTCGCGCACAGAC-3' (SEQ ID NO:55)
	3' primer for Shh-N:	5'-GGGAATCAGCCGTCAGATTTG-3' (SEQ ID NO:56)
	5' primer for Nurr1 and Nurr1a:	5'-TCGGCTGAAGCCATGCCTTG-3' (SEQ ID NO:57)
	3' primer for Nurr1 and Nurr1a:	5'-GACGTGCATGGGAGAAAAGTC-3' (SEQ ID NO:58)
5	5' primer for Ptx3:	5'-CATGGAGTTTGGGCTGCTTGG-3' (SEQ ID NO:59)
	3' primer for Ptx3:	5'-TCACACCGCCGTTCCACG-3' (SEQ ID NO:60)

The PCR products were subcloned into TOPO-TA cloning vector (Invitrogen) as described in the manufacturer's instructions. DNA sequencing confirmed that the clones contained the full length sequences for the rat Shh-N, Nurr1, Nurr1a, and Ptx3 coding regions.

## 2. Retroviral Cloning and Transduction

The NIT retroviral vector was constructed from LINX (Hoshimaru *et al.*, *Proc. Natl. Acad. Sci. USA* 93:1518-1523 (1996)) by swapping positions of the tetracycline-controlled transactivator (tTA) and neomycin resistance genes (Figure 2). The neomycin resistance gene was replaced by E-GFP coding sequence to form GIT. The transgenes within the NIT and GIT vectors are under the control of the CMV promoter fused to the tetracycline operator. RVEN3 was constructed from pCLMFG (provided by Nikunj Somia) by deleting the ATG codon between the splice acceptor site and multiple linker sites. The transgenes within the RVEN3 vector are under the control of the retrovirus LTR promoter. pCLMFG was derived from MFG and contains a hCMV immediate early promoter in place of the 5' U3 region in pCLMFG (Naviaux *et al.*, 1996). Fragments containing Shh-N, Nurr1, Nurr1a, Ptx3, and E-GFP (Clontech) were cloned into NIT, GIT, or RVEN3 vector and the DNA transfected into producer cells (293gag pol; provided from Nikunj Somia). To increase the degree of infection of the virus, viral preparations were pseudotyped with a vesicular stomatitis virus (VSV-G) coat protein by cotransfecting the producer cells with pMD.G. Viral supernatants were concentrated by centrifugation (Burns *et al.*, 1993) and exposed to AHPs suspensions for 30 minutes followed by plating to polyornithine/laminin-coated dishes.

To generate stable expressing cells, HC7 cells were treated with a high concentration of NIT-based viruses (multiplicity of infection = about 1) and cultured in the presence of 100 µg/ml G418. To improve cell survival during selection, medium was supplemented with conditioned medium from high density HC7 cell culture.

3. *Shh-N in proliferating cells potentiates TH expression during differentiation*

The role of Shh in AHPs was examined using a tetracycline suppressible Shh-N-expressing retrovirus (NIT-Shh-N; Figure 2). Shh-N is a recombinant amino-terminal autoproteolytic fragment of Shh. When NIT-Shh-N was introduced into AHPs and a bulk drug resistant population of stable Shh-N-expressing cells were isolated, a high level of Shh-N mRNA expression under control of a tetracycline repressible promoter was observed.

To examine the effects of Shh-N expressed only during the terminal stages of differentiation, AHPs (C31) were infected with a high titer of Shh-N expressing retrovirus immediately before differentiation. Interestingly, Shh-N expression resulted in depressed TH expression after 6 days of differentiation in the presence of RA (Figure 3, column a). Similar TH repression was observed in the stable Shh-N-expressing cells (HC7-Shh-N) when tetracycline was used to suppress Shh-N-expression until just before differentiation in the presence of RA (Figure 3, column b). In contrast, constitutive expression of Shh-N in proliferating cells (HC7-Shh-N) for 10 days prior to differentiation resulted in a 1.8-fold and 3.7-fold increase in TH expression after 6 days of differentiation in the presence of FK or RA, respectively (Figure 3, columns c and d). Interestingly, constitutive Shh expression had no effect on TH expression during proliferation. In addition, expression of DBH was not observed in any of these conditions. These results indicate that Shh can play an important role in the early patterning of proliferative precursors but has an inhibitory effect on TH expression when expressed during the terminal stages of differentiation.

#### 4. *Nurr1* induces TH expression

The roles of Nurr1 and Nurr1a (a COOH-terminal truncation of Nurr1 formed by alternative splicing) were examined. Nucleic acid encoding these polypeptides were subcloned into the retrovirus expression vectors NIT or RVEN3, and the resulting vectors used to transduce AHPs cultures (Figure 2). Nurr1-expressing retrovirus (NIT-Nurr1) was introduced into AHPs and a bulk population of stable Nurr1-expressing cells (HC7-Nurr1) was isolated by G418 selection. Nurr1 mRNA was expressed at 25-fold higher levels than in non-transduced controls, and TH expression was elevated 60-fold in proliferating cells (Figure 4). In addition, the 60-fold increase in TH expression was maintained during the rapid induction of TH observed in response to FGF-2 withdrawal and FK treatment. For example, at 24 hours following FGF-2 withdrawal, both control and Nurr1-expressing cells exhibited a 2-fold increase in TH expression but the absolute level of TH expression remained 60-fold higher in Nurr1-expressing cells compared to non-infected controls (Figure 5). By six days, this differential TH response was maintained but to a lesser extent. TH expression was 14-fold or 7-fold higher in Nurr1-expressing cells than in non-infected controls in the presence of RA and FK, respectively (Figure 6). Interestingly, Nurr1 had little effect on the proliferation of cells, and expression levels of Ptx3, AADC, c-Ret, and GFR- $\alpha$ 1 were not affected. In other words, forced expression of Nurr1 did not alter the proliferative state of the cells. Similar results were obtained using the stem cell-derived C31 line.

Overexpression of Nurr1a, the COOH-terminal truncated form of Nurr1, had little effect on TH expression, either in proliferating or differentiating cells (Figures 4-6). These results indicate that the alternatively spliced form of Nurr1 does not function to activate TH expression. In addition, the forced expression of Nurr1a did not negatively regulate the Nurr1 activation of TH expression in either control cells expressing endogenous levels of Nurr1 or HC7-Nurr1 overexpressing cells.

Forced expression of Nurr1 alone was not sufficient to induce TH expression in fibroblast and kidney cell lines. Specifically, the full length Nurr1 was introduced into the rat primary skin fibroblast cell line (FF12) and the human kidney cell line

(293 cells) using the RVEN3 retroviral vector. In both cases, TH expression was not detected.

In addition, TH polypeptide expression was examined by immunofluorescent staining. TH immunoreactivity was detected ubiquitously in HC7-Nurr1 cells in both  
5 proliferating and differentiating conditions. In addition, TH polypeptide was detected at low levels in all Nurr1-expressing cells; however, following differentiation in either RA or FK, TH expression was markedly upregulated in roughly 1% of the Map2ab-positive neurons. These strongly TH immunoreactive neurons were generated at similar numbers even in the absence of forced expression of Nurr1. These results  
10 indicate that Nurr1 overexpression can activate TH expression in undifferentiated cells yet not to the extent achieved during a fully activated neuronal differentiation program.

The Nurr1-induced expression of TH resulted in the synthesis of active TH enzyme. Cell lysates were analyzed for DOPA, dopamine, and DOPAC by reverse-  
15 phase high-performance liquid chromatography (HPLC). Briefly, cells were collected after 6 days of differentiation in N2 medium supplemented with FK or after 2 days of proliferation in the presence of FGF-2, and suspended in lysis buffer containing 100 mM perchloric acids, 50 mM EDTA pH 8.0, and 50 mM sodium bisulfate. Samples were freeze/thawed twice and supernatants were collected by centrifugation at 14,000  
20 rpm for 5 minutes. These samples were assayed for DOPA, dopamine, and DOPAC using reverse phase HPLC with electrochemical detection as described elsewhere (Melega *et al.*, *Brain Res.* 543:271-276 (1991)).

DOPA and DOPAC were detected in HC7-Nurr1 cell lysates after 6 days of differentiation in the presence of FK (Figure 7). The total amounts of DOPA and  
25 DOPAC were 49.2 ng/mg protein. Control HC7 cells did not produce detectable amounts of DOPA or DOPAC. These results indicate that the TH expression detected in Nurr1-expressing cells led to the production of functional TH enzyme. In addition, since DOPA is rapidly converted to dopamine by AADC and is subsequently converted to DOPAC by MAO and aldehyde dehydrogenase, the presence of DOPAC  
30 indicates that both TH and AADC are functional.

5. *Ptx3 had little effect on proliferation and differentiation*

The role of Ptx3 during proliferation and differentiation was examined. Nucleic acid encoding this polypeptide was subcloned into the retrovirus expression vector RVEN3, and the resulting Ptx3-containing expression vector was used to transduce Nurr1-stable cells (HC7-Nurr1). Ptx3 mRNA was easily detected in these cells; however, the expression of TH, AADC, c-Ret, GFR $\alpha$ -1, and D2R was not affected (Figure 4 and 6).

Since Ptx3-expressing cells may require Nurr1 for survival, HC7 cells were treated with a GFP-tagged retroviral vector (GIT) expressing Ptx3 so that individual Ptx3-expressing cells can be followed in a population of cells that express very low levels of endogenous Nurr1 (Figure 1). No differences in proliferation or differentiation relative to GFP expression alone were observed, indicating that Ptx3 overexpression does not itself induce apoptosis in cells expressing low levels of Nurr1.

Example 4 - Nurr1 polypeptide binds directly to a Nurr1 binding element within the TH promoter

Six kilobases of sequence upstream of the TH start site were scanned for putative Nurr1 binding sites. DNase I footprint analysis was performed using recombinant Nurr1 polypeptide and a DNA fragment corresponding to the rat TH promoter positions -962 to -729. Briefly, labeled TH DNA fragments (-962 to -729) used for footprint analysis were generated by PCR using a plasmid containing 4.5 kb of the rat TH promoter as template (provided by Chikaraishi ) and two oligo primers, one of which was <sup>32</sup>P end- labeled. The resulting PCR products were gel purified using 6% polyacrylamide gel. Nurr1 polypeptide was produced in a TNT coupled reticulocyte lysate system (Promega). DNase I footprint reactions were carried out in 25 mM HEPES-KOH pH 7.5, 80 mM potassium chloride, 1 mM magnesium chloride, 20% glycerol, 0.05% NP-40, and 5% polyvinyl alcohol with a fixed amount of reticulocyte lysate. Dose response experiments were performed using different ratios



of unreacted and reacted reticulocyte lysate. For example, the end-labeled fragments were incubated with 0, 10, 5, and 1 µl of reticulocyte lysate reaction mixture of Nurr1 polypeptide combined with 10, 0, 5, and 9 µl of unreacted reticulocyte lysate, respectively. DNase I digestions were carried out with 0.1 unit of enzyme at room temperature for one minute. DNA sequencing was performed by the same labeled primer using Sequenase kit (Amersham).

Titration of Nurr1 polypeptide gave progressive protection of nucleotides spanning positions -873 to -866 (5'-AAAGGTCA-3'). In contrast, Nurr1a exhibited only weak protection at the same site. Taken together, these data indicate that Nurr1 activates TH expression by binding directly to a midbrain dopaminergic neuron-specific enhancer element of the TH promoter.

To determine whether Nurr1 acts in a 9cRA-dependent or 9cRA-independent manner to induce TH expression, the effects of 9cRA on TH expression were examined. HC7-Nurr1 cells were exposed to FGF-2 withdrawal and treatment with 9cRA for 24 hours. FGF-2 withdrawal increased TH expression 2-fold. Addition of all-trans RA (RA) had no additional effect on TH expression at this very early time in differentiation. In contrast, TH expression decreased in the presence of 9cRA in a dose-dependent manner (Figure 5). These results indicate that the activating effects of Nurr1 on TH expression are not dependent on 9cRA.

## OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

**WHAT IS CLAIMED IS:**

1. A cell comprising exogenous nucleic acid, said exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent  
5 identical to the sequence set forth in SEQ ID NO:2, wherein said amino acid sequence is expressed and induces tyrosine hydroxylase expression within said cell.
2. The cell of claim 1, wherein said cell is a mammalian cell.
- 10 3. The cell of claim 2, wherein said cell is derived from an adult mammal.
4. The cell of claim 1, wherein said cell is a neural progenitor cell.
5. The cell of claim 4, wherein said cell is a midbrain neural progenitor cell.  
15
6. The cell of claim 1, wherein said cell is a neural cell.
7. The cell of claim 1, wherein said cell expresses at least one polypeptide selected from the group consisting of Otx1, En1, and Ptx3.  
20
8. The cell of claim 1, wherein said tyrosine hydroxylase expression promotes DOPA production in said cell.
9. The cell of claim 1, wherein said tyrosine hydroxylase expression promotes  
25 dopamine production in said cell.
10. The cell of claim 1, wherein said tyrosine hydroxylase expression promotes norepinephrine and epinephrine production in said cell.
- 30 11. The cell of claim 1, wherein said nucleic acid sequence encodes Nurr1.

12. A method for inducing tyrosine hydroxylase expression in a cell, said method comprising providing said cell with exogenous nucleic acid, said exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2, wherein said amino acid sequence is expressed and induces tyrosine hydroxylase expression within said cell.
13. The method of claim 12, wherein said cell is provided with said exogenous nucleic acid *in vivo*.
14. The method of claim 12, wherein said cell is provided with said exogenous nucleic acid *ex vivo*.
15. The method of claim 12, wherein said cell is a mammalian cell.
16. The method of claim 15, wherein said cell is derived from an adult mammal.
17. The method of claim 12, wherein said cell is a neural progenitor cell.
18. The method of claim 17, wherein said cell is a midbrain neural progenitor cell.
19. The method of claim 12, wherein said cell is a neural cell.
20. The method of claim 12, wherein said cell expresses at least one polypeptide selected from the group consisting of Otx1, En1, and Ptx3.
21. The method of claim 12, wherein said tyrosine hydroxylase expression promotes DOPA production in said cell.
22. The method of claim 12, wherein said tyrosine hydroxylase expression

promotes dopamine production in said cell.

23. The method of claim 12, wherein said tyrosine hydroxylase expression promotes norepinephrine production in said cell.

5

24. The method of claim 12, wherein said nucleic acid sequence encodes Nurr1.

25. A method for treating a catecholamine-related deficiency in a mammal, said method comprising administering an effective amount of cells to said mammal,  
10 wherein said cells contain exogenous nucleic acid, said exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2, and wherein said amino acid sequence is expressed and induces tyrosine hydroxylase expression in said cells thereby causing said cells to produce a catecholamine.

15

26. The method of claim 25, wherein said catecholamine-related deficiency comprises a dopamine deficiency.

27. The method of claim 26, wherein said catecholamine is dopamine.

20

28. The method of claim 25, wherein said catecholamine-related deficiency comprises a norepinephrine deficiency.

29. The method of claim 28, wherein said cells express dopamine  $\beta$ -hydroxylase,  
25 and wherein said catecholamine is norepinephrine.

30. The method of claim 25, wherein said catecholamine-related deficiency is associated with a disease state selected from the group consisting of Parkinson's disease, manic depression, and schizophrenia.

30 31. The method of claim 25, wherein said mammal is a human.

32. The method of claim 25, wherein said cells are mammalian cells.

33. The method of claim 32, wherein said cells are derived from an adult mammal.
34. The method of claim 25, wherein said cells are neural progenitor cells.
- 5 35. The method of claim 34, wherein said cells are midbrain neural progenitor cells.
36. The method of claim 25, wherein said cells are neural cells.
- 10 37. The method of claim 25, wherein said cells express at least one polypeptide selected from the group consisting of Otx1, En1, and Ptx3.
38. The method of claim 25, wherein said administration is an intracranial administration.
- 15 39. The method of claim 38, wherein said intracranial administration places said cells within the midbrain region of said mammal.
40. The method of claim 25, wherein said nucleic acid sequence encodes Nurr1.
- 20 41. A method for treating a catecholamine-related deficiency in a mammal, said method comprising administering an exogenous nucleic acid to a cell of said mammal, said exogenous nucleic acid having a nucleic acid sequence that encodes an amino acid sequence at least 65 percent identical to the sequence set forth in SEQ ID NO:2, wherein
- 25 said amino acid sequence is expressed and induces tyrosine hydroxylase expression in said cell thereby causing said cell to produce a catecholamine.
42. The method of claim 41, wherein said catecholamine-related deficiency comprises a dopamine deficiency.
- 30 43. The method of claim 42, wherein said catecholamine is dopamine.
44. The method of claim 41, wherein said catecholamine-related deficiency comprises a norepinephrine deficiency.

45. The method of claim 44, wherein said cell expresses dopamine  $\beta$ -hydroxylase, and wherein said catecholamine is norepinephrine.
- 5 46. The method of claim 41, wherein said catecholamine-related deficiency is associated with a disease state selected from the group consisting of Parkinson's disease, manic depression, and schizophrenia.
47. The method of claim 41, wherein said mammal is a human.
- 10 48. The method of claim 41, wherein said cell is a mammalian cell.
49. The method of claim 48, wherein said cell is derived from an adult mammal.
- 15 50. The method of claim 41, wherein said cell is a neural progenitor cell.
51. The method of claim 50, wherein said cell is a midbrain neural progenitor cell.
52. The method of claim 41, wherein said cell is a neural cell.
- 20 53. The method of claim 41, wherein said cell expresses at least one polypeptide selected from the group consisting of Otx1, En1, and Ptx3.
54. The method of claim 41, wherein said nucleic acid sequence encodes Nurr1.
- 25 55. A method for identifying a tyrosine hydroxylase-related deficiency in a mammal, said method comprising detecting a mutation in a Nurr1-binding element in a tyrosine hydroxylase promoter, wherein said Nurr1-binding element promotes tyrosine hydroxylase expression when bound by Nurr1 polypeptide, and wherein the presence of
- 30 said mutation is indicative of a tyrosine hydroxylase-related deficiency.
56. The method of claim 55, wherein said tyrosine hydroxylase-related deficiency is associated with a disease state selected from the group consisting of Parkinson's disease,

manic depression, and schizophrenia.

57. The method of claim 55, wherein said mammal is a human.

5 58. The method of claim 55, wherein said mutation comprises at least one nucleotide change in said Nurr1-binding element.

59. The method of claim 55, wherein said Nurr1-binding element comprises a sequence as set forth in 5'-AAAGGTCA-3'.

10

60. A kit for inducing tyrosine hydroxylase expression in a cell, said kit comprising a proliferation factor and nucleic acid, wherein said proliferation factor promotes proliferation of said cell, and wherein said nucleic acid is exogenous to said cell and comprises a nucleic acid sequence that encodes an amino acid sequence at  
15 least 65 percent identical to the sequence set forth in SEQ ID NO:2.

61. The kit of claim 60, wherein said cell is a neural progenitor cell.

62. The kit of claim 60, wherein said cell is neural cell.

20

63. The kit of claim 60, wherein said proliferation factor comprises FGF-2.

64. The kit of claim 60, wherein said nucleic acid sequence encodes Nurr1.

25 65. A cell comprising exogenous nucleic acid, wherein said exogenous nucleic acid encodes an amino acid sequence, and hybridizes to the sequence set forth in SEQ ID NO:1 under hybridization conditions, and wherein said amino acid sequence is expressed and induces tyrosine hydroxylase expression within said cell.

1/8




FIG. 1



2/8








FIG. 2

3/8



4/8



5/8





FIG. 5






FIG. 6E




FIG. 6G




FIG. 6D







FIG. 6F



## SEQUENCE LISTING

&lt;110&gt; The Salk Institute for Biological Studies

<120> REGULATION OF TYROSINE HYDROXYLASE  
EXPRESSION

&lt;130&gt; SALK2710WO

&lt;140&gt; PCT/US00/-----

&lt;141&gt; 2000-03-21

&lt;150&gt; 09/277,078

&lt;151&gt; 1999-03-26

&lt;160&gt; 60

&lt;170&gt; FastSEQ for Windows Version 4.0

&lt;210&gt; 1

&lt;211&gt; 1797

&lt;212&gt; DNA

&lt;213&gt; Rattus norvegicus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(900)

&lt;400&gt; 1

atg cct tgt gtt cag gcg cag tat ggg tcc tcg cct caa gga gcc agc	48
Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser	
1 5 10 15	

ccc gct tct cag agc tac agt tac cac tct tcg gga gaa tac agc tcc	96
Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser	
20 25 30	

gat ttc tta act cca gag ttt gtc aag ttt agc atg gac ctc acc aac	144
Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn	
35 40 45	

act gaa att act gcc acc act tct ctc ccc agc ttc agt acc ttt atg	192
Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met	
50 55 60	

gac aac tac agc aca ggc tac gac gtc aag cca cct tgc ttg tac caa	240
Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln	
65 70 75 80	

atg ccc ctg tcc gga cag cag tcc tcc att aag gta gaa gac att cag	288
Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln	
85 90 95	

atg cac aac tac cag caa cac agc cac ctg ccc cct cag tcc gag gag	336
Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu	
100 105 110	

atg atg cca cac agc ggg tcg gtt tac tac aag ccc tct tcg ccc ccg	384
---	-----



Met	Met	Pro	His	Ser	Gly	Ser	Val	Tyr	Tyr	Lys	Pro	Ser	Ser	Pro	Pro	
	115						120					125				
aca	ccc	agc	acc	ccg	ggc	ttc	cag	gtg	cag	cat	agc	ccg	atg	tgg	gac	432
Thr	Pro	Ser	Thr	Pro	Gly	Phe	Gln	Val	Gln	His	Ser	Pro	Met	Trp	Asp	
	130					135					140					
gat	ccg	ggc	tcc	ctt	cac	aac	ttc	cac	cag	aac	tac	gtg	gcc	act	acg	480
Asp	Pro	Gly	Ser	Leu	His	Asn	Phe	His	Gln	Asn	Tyr	Val	Ala	Thr	Thr	
	145				150					155					160	
cat	atg	atc	gag	cag	agg	aag	aca	cct	gtc	tcc	cgc	ctt	tca	ctc	ttc	528
His	Met	Ile	Glu	Gln	Arg	Lys	Thr	Pro	Val	Ser	Arg	Leu	Ser	Leu	Phe	
			165					170						175		
tcc	ttt	aag	cag	tcg	ccc	ccg	ggc	act	cct	gtg	tct	agc	tgc	cag	atg	576
Ser	Phe	Lys	Gln	Ser	Pro	Pro	Gly	Thr	Pro	Val	Ser	Ser	Cys	Gln	Met	
		180						185					190			
cgc	ttt	gac	ggg	cct	ctg	cac	gtc	ccc	atg	aac	ccg	gag	ccc	gcg	ggc	624
Arg	Phe	Asp	Gly	Pro	Leu	His	Val	Pro	Met	Asn	Pro	Glu	Pro	Ala	Gly	
	195						200					205				
agc	cac	cac	gta	ctg	gat	ggg	cag	acc	ttc	gcc	gtg	ccc	aat	ccc	att	672
Ser	His	His	Val	Leu	Asp	Gly	Gln	Thr	Phe	Ala	Val	Pro	Asn	Pro	Ile	
	210					215					220					
cgc	aag	ccg	gca	tcc	atg	ggc	ttc	ccg	ggc	ctg	cag	atc	ggc	cac	gcg	720
Arg	Lys	Pro	Ala	Ser	Met	Gly	Phe	Pro	Gly	Leu	Gln	Ile	Gly	His	Ala	
	225				230					235					240	
tcg	cag	ttg	ctt	gac	acg	cag	gtg	ccc	tcg	ccg	ccg	tcc	cgg	ggc	tct	768
Ser	Gln	Leu	Leu	Asp	Thr	Gln	Val	Pro	Ser	Pro	Pro	Ser	Arg	Gly	Ser	
			245					250						255		
ccc	tcc	aat	gag	ggg	ctg	tgc	gct	gtt	tgc	ggg	gac	aac	gcg	gcc	tgt	816
Pro	Ser	Asn	Glu	Gly	Leu	Cys	Ala	Val	Cys	Gly	Asp	Asn	Ala	Ala	Cys	
		260						265					270			
cag	cat	tac	ggg	gtt	cgc	act	tgt	gag	ggc	tgc	aaa	ggg	ttc	ttt	aag	864
Gln	His	Tyr	Gly	Val	Arg	Thr	Cys	Glu	Gly	Cys	Lys	Gly	Phe	Phe	Lys	
	275						280						285			
cgc	acg	gtg	caa	aaa	aac	gcg	aaa	tat	gtg	tgt	tta	gcaaataaaa				910
Arg	Thr	Val	Gln	Lys	Asn	Ala	Lys	Tyr	Val	Cys	Leu					
	290					295					300					
attgcccagt	ggataagcgc	cgccgaaatc	gttgtcagta	ctgtcggttt	cagaagtgc											970
tggctgttgg	gatggttaaa	gaagtgggtc	gcacggacag	tttaaaaggc	cggagaggtc											1030
gtctaccctc	aaaaccgaag	agccacacagg	atccctctc	cccctcacct	ccggtgagtc											1090
tgatcagtg	cctcgtcaga	gcccacgtcg	actccaatcc	ggcaatgacc	agcctggact											1150
attccagggt	ccaggcaaac	cctgactatc	agatgagtg	agatgatact	caacatatcc											1210
agcagttcta	cgatctcctg	actggctcta	tggagatcat	cagaggggtg	gcagagaaga											1270
ttcctggctt	tgctgacctg	cccaaagccg	atcaggacct	gctttttgaa	tcagctttct											1330
tagaattatt	tggtctacgc	ttagcataca	ggtccaaccc	agtggagggg	aaactcatct											1390
tttgcaatgg	ggtggtcttg	cacaggttgc	aatgcgtgcg	tggctttggg	gaatggattg											1450
attccattgt	tgaattctcc	tccaacttgc	agaatatgaa	catcgacatt	tctgccttct											1510
cctgcattgc	tgccctggct	atgggtcacag	agagacacgg	gctcaaggaa	cccaagagag											1570
tggaagagct	acaaaacaaa	attgtaaatt	gtcttaagaa	ccatgtgact	ttcaataatg											1630

```

ggggattgaa cggacccaac tacctgtcca aactgttggg gaagctccca gaacttcgca 1690
ccctttgcac acaggggctc cagcgcatTT tctacctgaa attggaagac ttggtaccac 1750
caccagcaat aattgacaaa cttttcctgg acaccttacc tttctaa 1797

```

<210> 2  
 <211> 300  
 <212> PRT  
 <213> Rattus norvegicus

```

<400> 2
Met Pro Cys Val Gln Ala Gln Tyr Gly Ser Ser Pro Gln Gly Ala Ser
1      5      10      15
Pro Ala Ser Gln Ser Tyr Ser Tyr His Ser Ser Gly Glu Tyr Ser Ser
20      25      30
Asp Phe Leu Thr Pro Glu Phe Val Lys Phe Ser Met Asp Leu Thr Asn
35      40      45
Thr Glu Ile Thr Ala Thr Thr Ser Leu Pro Ser Phe Ser Thr Phe Met
50      55      60
Asp Asn Tyr Ser Thr Gly Tyr Asp Val Lys Pro Pro Cys Leu Tyr Gln
65      70      75      80
Met Pro Leu Ser Gly Gln Gln Ser Ser Ile Lys Val Glu Asp Ile Gln
85      90      95
Met His Asn Tyr Gln Gln His Ser His Leu Pro Pro Gln Ser Glu Glu
100     105     110
Met Met Pro His Ser Gly Ser Val Tyr Tyr Lys Pro Ser Ser Pro Pro
115     120     125
Thr Pro Ser Thr Pro Gly Phe Gln Val Gln His Ser Pro Met Trp Asp
130     135     140
Asp Pro Gly Ser Leu His Asn Phe His Gln Asn Tyr Val Ala Thr Thr
145     150     155     160
His Met Ile Glu Gln Arg Lys Thr Pro Val Ser Arg Leu Ser Leu Phe
165     170     175
Ser Phe Lys Gln Ser Pro Pro Gly Thr Pro Val Ser Ser Cys Gln Met
180     185     190
Arg Phe Asp Gly Pro Leu His Val Pro Met Asn Pro Glu Pro Ala Gly
195     200     205
Ser His His Val Leu Asp Gly Gln Thr Phe Ala Val Pro Asn Pro Ile
210     215     220
Arg Lys Pro Ala Ser Met Gly Phe Pro Gly Leu Gln Ile Gly His Ala
225     230     235     240
Ser Gln Leu Leu Asp Thr Gln Val Pro Ser Pro Pro Ser Arg Gly Ser
245     250     255
Pro Ser Asn Glu Gly Leu Cys Ala Val Cys Gly Asp Asn Ala Ala Cys
260     265     270
Gln His Tyr Gly Val Arg Thr Cys Glu Gly Cys Lys Gly Phe Phe Lys
275     280     285
Arg Thr Val Gln Lys Asn Ala Lys Tyr Val Cys Leu
290     295     300

```

<210> 3  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Oligonucleotide for PCR

<400> 3  
 accacagtcc atgccatcac

<210> 4  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 4  
tccaccaccc tgttgctgta 20

<210> 5  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 5  
cctccttgct tcgggctgta a 21

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 6  
ctgagcttgt ccttggcgctc a 21

<210> 7  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 7  
cctactggct gctcggacta a 21

<210> 8  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 8  
gcgtaccagg gactcaaact c 21

<210> 9  
<211> 21  
<212> DNA

<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 9  
gtgaccagaa agggcagatc c 21

<210> 10  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 10  
caccggcttc ttctgggtag t 21

<210> 11  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 11  
gcagacctca cagacgttgc t 21

<210> 12  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 12  
aggctggttt ctcgatctg g 21

<210> 13  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 13  
tggcgctcaa gatcgacctc a 21

<210> 14  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 14  
cgttaggggtg ggattagcgg t 21

<210> 15  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 15  
taaaaggccg gagaggtcgt c 21

<210> 16  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 16  
ctctcttggg ttccttgagc c 21

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 17  
acctttggac tgcttctggg 20

<210> 18  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 18  
agtcgtagcc cctgaagtgt t 21

<210> 19  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 19  
gccaccctgc tcatctgga 19

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 20  
ttccggccta aacgcttctc 20

<210> 21  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 21  
catgtgtgag caagaagggt gc 22

<210> 22  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 22  
aagtcgagga cactggctat agg 23

<210> 23  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 23  
ttctggtggc ccttgcttcc t 21

<210> 24  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 24  
tacttgctgc ggtccctgtc a 21

<210> 25  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Amino Acid sequence representing a degenerate primer for PCR

<400> 25

Met Gly Ile Met Gly Ile Gly Ala Arg Met Gly Ile Ala Cys Ile Ala  
1 5 10 15  
Cys Ile Thr Thr Tyr Ala Cys  
20

<210> 26

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 26

Ile Cys Lys Ile Cys Lys Arg Thr Thr Ile Asx Trp Arg Ala Ala Cys  
1 5 10 15  
Cys Ala Ile Ala Cys Tyr Thr Gly  
20

<210> 27

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 27

Ala Ala Arg Met Gly Ile Cys Cys Ile Met Gly Ile Ala Cys Ile Gly  
1 5 10 15  
Cys Ile Thr Thr Tyr Ala Cys  
20

<210> 28

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 28

Cys Lys Tyr Thr Thr Arg Thr Thr Tyr Thr Gly Arg Ala Ala Cys Cys  
1 5 10 15  
Ala Asp Ala Thr Tyr Thr Thr  
20

<210> 29

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 29

Tyr Thr Ile Gly Ala Arg Ala Ala Arg Gly Ala Arg Thr Thr Tyr Cys  
 1 5 10 15  
 Ala Tyr Thr Thr Tyr Ala Ala  
 20

<210> 30

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 30

Thr Thr Cys Ala Thr Ile Cys Lys Ile Cys Lys Arg Thr Thr Tyr Thr  
 1 5 10 15  
 Gly Arg Ala Ala Cys Cys Ala  
 20

<210> 31

<211> 23

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 31

Met Gly Ile Met Gly Ile Trp Ser Ile Met Gly Ile Ala Cys Ile Ala  
 1 5 10 15  
 Cys Ile Thr Thr Tyr Ala Cys  
 20

<210> 32

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino Acid representing degenerate primer for PCR

<400> 32

Ile Cys Lys Ile Cys Lys Arg Thr Thr Ile Asx Trp Arg Ala Ala Cys  
 1 5 10 15  
 Cys Ala Ile Ala Cys Tyr Thr Gly  
 20

<210> 33

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for PCR

<400> 33



gcatacctgaa cctgtgtgcc a 21

<210> 34  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 34  
gcagcaccct tgagtgggtg c 21

<210> 35  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 35  
gatttgctga tgtccgccga g 21

<210> 36  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 36  
aatcagtcct gagtaggcca g 21

<210> 37  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 37  
agacagaccc aggttcgct a 21

<210> 38  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Oligonucleotide for PCR

<400> 38  
tttccgctga tgcaatgggc g 21

<210> 39  
<211> 20

```

<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for PCR

<221> misc_feature
<222> (0)...(0)
<223> n = A, T, G, or C

<221> misc_feature
<222> (0)...(0)
<223> r = G or A

<400> 39
tcngagatgg agrtgatgaa                                20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for PCR

<221> misc_feature
<222> (0)...(0)
<223> h = A, C, or T; not G

<221> misc_feature
<222> (0)...(0)
<223> d = A, G, or T; not C

<400> 40
ccaaagtchg cdatcttcac                                20

<210> 41
<211> 157
<212> DNA
<213> Rattus norvegicus

<220>
<221> CDS
<222> (1)...(157)

<400> 41
cgg cgg gag cgg acg acg ttt acg cgc tca cag ctg gac gtg ctc gag      48
Arg Arg Glu Arg Thr Thr Phe Thr Arg Ser Gln Leu Asp Val Leu Glu
 1             5             10             15

gcg ctg ttc gca aag act cgc tac cca gac atc ttc atg cgc gag gag      96
Ala Leu Phe Ala Lys Thr Arg Tyr Pro Asp Ile Phe Met Arg Glu Glu
      20             25             30

gtg gct ctc aag atc aac ctg ccc gag tcc aga gtc caa gtc tgg ttc      144
Val Ala Leu Lys Ile Asn Leu Pro Glu Ser Arg Val Gln Val Trp Phe
      35             40             45

aac aac agc cgc c                                157

```

Asn Asn Ser Arg  
50

<210> 42  
<211> 52  
<212> PRT  
<213> Rattus norvegicus

<400> 42  
Arg Arg Glu Arg Thr Thr Phe Thr Arg Ser Gln Leu Asp Val Leu Glu  
1 5 10 15  
Ala Leu Phe Ala Lys Thr Arg Tyr Pro Asp Ile Phe Met Arg Glu Glu  
20 25 30  
Val Ala Leu Lys Ile Asn Leu Pro Glu Ser Arg Val Gln Val Trp Phe  
35 40 45  
Asn Asn Ser Arg  
50

<210> 43  
<211> 156  
<212> DNA  
<213> Rattus norvegicus

<220>  
<221> CDS  
<222> (1)...(156)

<400> 43  
aag cgg ccg cgg acg gcg ttc acg gcc gag cag ctg cag aga ctc aag 48  
Lys Arg Pro Arg Thr Ala Phe Thr Ala Glu Gln Leu Gln Arg Leu Lys  
1 5 10 15  
gcg gag ttc cag gca aac cgc tac atc acg gag cag cgg cga cag acc 96  
Ala Glu Phe Gln Ala Asn Arg Tyr Ile Thr Glu Gln Arg Arg Gln Thr  
20 25 30  
ctg gcc cag gag ctc agc ctg aac gag tcc cag atc aag atc tgg ttc 144  
Leu Ala Gln Glu Leu Ser Leu Asn Glu Ser Gln Ile Lys Ile Trp Phe  
35 40 45  
caa aac aag cga  
Gln Asn Lys Arg 156  
50

<210> 44  
<211> 52  
<212> PRT  
<213> Rattus norvegicus

<400> 44  
Lys Arg Pro Arg Thr Ala Phe Thr Ala Glu Gln Leu Gln Arg Leu Lys  
1 5 10 15  
Ala Glu Phe Gln Ala Asn Arg Tyr Ile Thr Glu Gln Arg Arg Gln Thr  
20 25 30  
Leu Ala Gln Glu Leu Ser Leu Asn Glu Ser Gln Ile Lys Ile Trp Phe  
35 40 45  
Gln Asn Lys Arg

50

<210> 45  
 <211> 156  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> CDS  
 <222> (1)...(156)

<400> 45  
 aag cgg ccg cgg acg gcg ttt acc agc gag cag ctg ctg gag ctg gag 48  
 Lys Arg Pro Arg Thr Ala Phe Thr Ser Glu Gln Leu Leu Glu Leu Glu  
 1 5 10 15  
 aag gaa ttc cac tgc aaa aag tac ctc tcc ctg acc gag cgc tca cag 96  
 Lys Glu Phe His Cys Lys Lys Tyr Leu Ser Leu Thr Glu Arg Ser Gln  
 20 25 30  
 atc gcc cat gcc ctc aaa ctc agc gag gtg caa gta aaa ata tgg ttc 144  
 Ile Ala His Ala Leu Lys Leu Ser Glu Val Gln Val Lys Ile Trp Phe  
 35 40 45  
 caa aac aag cga 156  
 Gln Asn Lys Arg  
 50

<210> 46  
 <211> 52  
 <212> PRT  
 <213> Rattus norvegicus

<400> 46  
 Lys Arg Pro Arg Thr Ala Phe Thr Ser Glu Gln Leu Leu Glu Leu Glu  
 1 5 10 15  
 Lys Glu Phe His Cys Lys Lys Tyr Leu Ser Leu Thr Glu Arg Ser Gln  
 20 25 30  
 Ile Ala His Ala Leu Lys Leu Ser Glu Val Gln Val Lys Ile Trp Phe  
 35 40 45  
 Gln Asn Lys Arg  
 50

<210> 47  
 <211> 111  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> CDS  
 <222> (1)...(111)

<400> 47  
 ctg gag aag gag ttc cat ttc aac aag tac cta aca aga gcc cgc agg 48  
 Leu Glu Lys Glu Phe His Phe Asn Lys Tyr Leu Thr Arg Ala Arg Arg  
 1 5 10 15  
 gtg gag ata gcc gcg tcc ctg caa ctc aat gag acc cag gtg aag atc 96  
 13

Val Glu Ile Ala Ala Ser Leu Gln Leu Asn Glu Thr Gln Val Lys Ile  
                   20                                  25                                  30

tgg ttc caa aac cgc  
 Trp Phe Gln Asn Arg  
                   35  
 111

<210> 48  
 <211> 37  
 <212> PRT  
 <213> Rattus norvegicus

<400> 48  
 Leu Glu Lys Glu Phe His Phe Asn Lys Tyr Leu Thr Arg Ala Arg Arg  
   1                                  5                                  10                                  15  
 Val Glu Ile Ala Ala Ser Leu Gln Leu Asn Glu Thr Gln Val Lys Ile  
                                   20                                  25                                  30  
 Trp Phe Gln Asn Arg  
                   35

<210> 49  
 <211> 111  
 <212> DNA  
 <213> Rattus norvegicus

<220>  
 <221> CDS  
 <222> (1)...(111)

<400> 49  
 ctg gag aag gag ttt cat ttc aac aag tac ctg tgc cgg ccg cgg cgg  
 Leu Glu Lys Glu Phe His Phe Asn Lys Tyr Leu Cys Arg Pro Arg Arg  
   1                                  5                                  10                                  15  
 48

gtt gag atc gcc gcc ttg ctg gac ctc acc gaa agg cag gtc aaa gtc  
 Val Glu Ile Ala Ala Leu Leu Asp Leu Thr Glu Arg Gln Val Lys Val  
                                   20                                  25                                  30  
 96

tgg ttc caa aac cgc  
 Trp Phe Gln Asn Arg  
                   35  
 111

<210> 50  
 <211> 37  
 <212> PRT  
 <213> Rattus norvegicus

<400> 50  
 Leu Glu Lys Glu Phe His Phe Asn Lys Tyr Leu Cys Arg Pro Arg Arg  
   1                                  5                                  10                                  15  
 Val Glu Ile Ala Ala Leu Leu Asp Leu Thr Glu Arg Gln Val Lys Val  
                                   20                                  25                                  30  
 Trp Phe Gln Asn Arg  
                   35

<210> 51  
 <211> 111

&lt;212&gt; DNA

&lt;213&gt; Rattus norvegicus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(111)

&lt;400&gt; 51

ctg	gag	aag	gag	ttc	cat	ttc	aac	cgc	tac	ctg	tgc	cgg	ccg	cgc	cgc		48
Leu	Glu	Lys	Glu	Phe	His	Phe	Asn	Arg	Tyr	Leu	Cys	Arg	Pro	Arg	Arg		
1				5					10					15			

gtg	gag	atg	gct	aac	ctg	ctg	aac	ctc	acc	gaa	cgc	cag	atc	aag	atc		96
Val	Glu	Met	Ala	Asn	Leu	Leu	Asn	Leu	Thr	Glu	Arg	Gln	Ile	Lys	Ile		
			20				25						30				

tgg	ttc	caa	aac	cgc													111
Trp	Phe	Gln	Asn	Arg													
			35														

&lt;210&gt; 52

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 52

Leu	Glu	Lys	Glu	Phe	His	Phe	Asn	Arg	Tyr	Leu	Cys	Arg	Pro	Arg	Arg		
1				5					10					15			
Val	Glu	Met	Ala	Asn	Leu	Leu	Asn	Leu	Thr	Glu	Arg	Gln	Ile	Lys	Ile		
			20				25						30				

Trp	Phe	Gln	Asn	Arg													
			35														

&lt;210&gt; 53

&lt;211&gt; 111

&lt;212&gt; DNA

&lt;213&gt; Rattus norvegicus

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)...(111)

&lt;400&gt; 53

ctg	gaa	aag	gaa	ttt	cat	ttt	aac	agg	tat	ctg	acc	agg	cgc	cgt	cgg		48
Leu	Glu	Lys	Glu	Phe	His	Phe	Asn	Arg	Tyr	Leu	Thr	Arg	Arg	Arg	Arg		
1				5					10					15			

att	gaa	atc	gct	cac	acc	ctg	tgt	ctg	tct	gag	cgc	cag	atc	aag	atc		96
Ile	Glu	Ile	Ala	His	Thr	Leu	Cys	Leu	Ser	Glu	Arg	Gln	Ile	Lys	Ile		
			20				25						30				

tgg	ttt	caa	aac	aaa													111
Trp	Phe	Gln	Asn	Lys													
			35														

&lt;210&gt; 54

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 54

```

Leu Glu Lys Glu Phe His Phe Asn Arg Tyr Leu Thr Arg Arg Arg Arg
 1           5           10           15
Ile Glu Ile Ala His Thr Leu Cys Leu Ser Glu Arg Gln Ile Lys Ile
      20           25           30
Trp Phe Gln Asn Lys
      35

```

&lt;210&gt; 55

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotides for PCR

&lt;400&gt; 55

cgtaccagct cgcgcacaga c

21

&lt;210&gt; 56

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotides for PCR

&lt;400&gt; 56

gggaatcagc cgtcagattt g

21

&lt;210&gt; 57

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotides for PCR

&lt;400&gt; 57

tcggctgaag ccatgccttg

20

&lt;210&gt; 58

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Oligonucleotides for PCR

&lt;400&gt; 58

gacgtgcatg ggagaaagtc

20

&lt;210&gt; 59

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<220>

<223> Oligonucleotides for PCR

<400> 59

catggagttt gggctgcttg g

21

<210> 60

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotides for PCR

<400> 60

tcacaccggc cggtccacg

19



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07544

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :C12N 15/00, 15/06, 15/09

US CL :435/252.3, 440, 455, 183, 69.1, 6

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/252.3, 440, 455, 183, 69.1, 6; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	SAKURADA et al. Nurrl, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development. September 1999, Vol. 126, No. 18, pages 4017-4026, see entire document.	1-24 and 65
Y	LAW et al. Identification of a New Brain-Specific Transcription Factor, NURR1. Molecular Endocrinology. December 1992, Vol. 6, No. 12, pages 2129- 2135. see entire document.	1-24 and 65

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 MAY 2000

Date of mailing of the international search report

25 JUL 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

  
RICHARD HUTSON

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07544

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - Y	SCEARCE et al. RNR-1, a nuclear Receptor in the NGFI-B/Nur77 Family That is Rapidly Induced in Regenerating Liver. J. Biol. Chem. April 1993, Vol. 268, No. 12, pages 8855-8861, see entire document.	1-3 and 65 ---- 4-24
X - Y	WO 94/04675 A2 (KROCZEK et al.) 03 March 1994, see entire document.	1-3 and 65 ---- 4-24
Y	CASTILLO et al. Dopamine Biosynthesis is Selectively Abolished in Substantia Nigra/Ventral Tegmental Area but not in Hypothalamic Neurons in Mice with Targeted Disruption of the Nurr1 Gene. Mol. Cell. Neuroscience. May 1998, Vol. 11, pages 36-46, see entire document.	1-24 and 65
A	NAKAGAWA et al. Roles of cell-autonomous mechanisms for differential expression of region-specific transcription factors in neuroepithelial cells. Development. August 1996, Vol. 122, No. 8, pages 2449-2464, see entire document.	1-24 and 65

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07544

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-24 and 65

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/07544

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

EAST, STN, MEDLINE, BIOSIS, CAPLUS, EMBASE, SCISEARCH, JAPIO, PATOSWO, PATOSEP; search terms: tyrosine hydroxylase, Nurr1, brain, midbrain, DOPA, dopamine, catecholamine, norepinephrine, otx1, en1 ptx1; STIC Search SEQ ID NO:1, 2 and 3,

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-24 and 65, drawn to a cell comprising exogenous nucleic acid that induces tyrosine hydroxylase expression and methods of inducing tyrosine hydroxylase expression.

Group II, claim(s) 25-54, drawn to a method of treating a catecholamine-related deficiency.

Group III, claim(s) 55-59, drawn to a method for detecting tyrosine hydroxylase-related deficiency in a mammal.

Group IV, claim(s) 60-64, drawn to a kit for inducing tyrosine hydroxylase expression in a cell.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The groups I-IV share the technical relationship of the Nurr1 protein sequence corresponding to SEQ ID No: 2, but the sequence of the Nurr1 protein was already known, (Law et al. Mol. Endocrinol. 6(12): 2129-2135, 1992) therefore this is not a special technical feature.